지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
이용수
등록된 정보가 없습니다.
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression
Clinical and Molecular Hepatology
2024 .04
Clinical impact of five cardiometabolic risk factors in metabolic dysfunction-associated steatotic liver disease (MASLD): Insights into regional and ethnic differences
Clinical and Molecular Hepatology
2024 .04
Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”
Clinical and Molecular Hepatology
2024 .04
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
Clinical and Molecular Hepatology
2024 .07
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
Clinical and Molecular Hepatology
2024 .07
Three-Step Algorithm for Screening High-Risk Group of Metabolic Dysfunction-Associated Steatotic Liver Disease in General Population
Gut and Liver
2024 .03
Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study
Clinical and Molecular Hepatology
2024 .04
Diverse Functions of Macrophages in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease: Bridging Inflammation and Metabolism
Immune Network
2025 .02
Effects of Metabolic Dysfunction-Associated Steatotic Liver Disease on Bone Density and Fragility Fractures: Associations and Mechanisms
Journal of Obesity & Metabolic Syndrome
2024 .06
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Clinical and Molecular Hepatology
2024 .07
[S8-4] Emerging insights: MASH-associated HCC progression
한국실험동물학회 학술발표대회 논문집
2024 .07
Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
Clinical and Molecular Hepatology
2024 .04
Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD
Clinical and Molecular Hepatology
2024 .01
WFDC2 exacerbates metabolic dysfunction associated steatotic liver disease
한국실험동물학회 학술발표대회 논문집
2025 .02
Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease
Clinical and Molecular Hepatology
2024 .07
A New Korean Nomenclature for Steatotic Liver Disease
Gut and Liver
2024 .09
Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD
Clinical and Molecular Hepatology
2024 .04
Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Clinical and Molecular Hepatology
2024 .01
Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”
Clinical and Molecular Hepatology
2024 .01
No More NAFLD: The Term Is Now MASLD
Endocrinology and Metabolism
2024 .02
0